

Investigación Publicaciones Científicas

Selección de los artículos con IF publicados por el Servicio de Oncología Médica en los últimos cinco años:

- Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. *Oncologist*. 2012 Jan 10.
- Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Díaz-Rubio E. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). *Ann Oncol*. 2011 Dec 9.
- Grávalos C, García-Alfonso P, Alfonso R, Arrazubi V, Arrivi A, Cámara JC, Capdevila J, Gómez-España A, Lacasta A, Manzano JL, Salgado M, Sastre J, Díaz-Rubio E. Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain. *Clin Transl Oncol*. 2011 Dec;13(12):862-8.
- Romero A, Martín M, Oliva B, de la Torre J, Furio V, de la Hoya M, García-Sáenz JA, Moreno A, Román JM, Díaz-Rubio E, Caldés T. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. *Ann Oncol*. 2011 Nov 2.
- Vieitez JM, García-Carbonero R, Aparicio J, Feliu J, González-Flores E, Grande E, Pérez-Hoyos T, Salud A, Torres E, Valero M, Valladares-Ayerbes M, Díaz-Rubio E. Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. *Clin Transl Oncol*. 2011 Nov;13(11):798-804.
- Romero A, Martín M, Oliva B, de la Torre J, Furio V, de la Hoya M, García-Sáenz JA, Moreno A, Román JM, Díaz-Rubio E, Caldés T. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. *Ann Oncol*. 2011 Nov 2.
- Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. *Ann Oncol*. 2011 Sep 6.
- Alonso Gordo T, García-Sáenz JA, Rodríguez Moreno JF, Hernández Pérez FJ, Díaz-Rubio E. Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome? *Clin Transl Oncol*. 2011 Jul;13(7):451-9.
- Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. *Br J Cancer*. 2011 Jun 28;105(1):58-64.
- Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Díaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcborg J. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. *Ann Oncol*. 2011 Jun;22 Suppl 5:v1-9.
- Romero A, Pérez-Segura P, Tosar A, García-Saenz JA, Díaz-Rubio E, Caldés T, de la Hoya M. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. *Breast Cancer Res Treat*. 2011 Oct;129(3):939-46. Epub 2011 May 3.
- Martín M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-

- Tarruella S, Díaz-Rubio E, Perou CM. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. *Breast Cancer Res Treat.* 2011 Jul;128(1):127-36. Epub 2011 Apr 5.
- Feliu Batlle J, Cuadrado E, Castro J, Caldés T, Belda C, Sastre J, Barriuso J, Martínez Marín V, Díaz-Rubio E, González-Barón M. Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study. *Chemotherapy.* 2011;57(2):138-44. Epub 2011 Mar 30.
 - Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. *Am J Pathol.* 2011 Apr;178(4):1453-60. Review.
 - Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. *Clin Transl Oncol.* 2011 Mar;13(3):162-78. Review.
 - Garre P, Briceño V, Xicola RM, Doyle BJ, de la Hoya M, Sanz J, Llovet P, Pescador P, Puente J, Díaz-Rubio E, Llor X, Caldés T. Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC). *Clin Cancer Res.* 2011 Apr 1;17(7):1701-12. Epub 2011 Feb 25.
 - Caronia D, Martín M, Sastre J, de la Torre J, García-Sáenz JA, Alonso MR, Moreno LT, Pita G, Díaz-Rubio E, Benítez J, González-Neira A. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. *Clin Cancer Res.* 2011 Apr 1;17(7):2006-13. Epub 2011 Feb 16.
 - García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. *Clin Transl Oncol.* 2011 Feb;13(2):121-32. Review.
 - Sastre J, Custodio A, Sanchez JC, Ortega L, Rodríguez L, Puente J, Corona J, Alfonso R, de las Heras M, Díaz-Rubio E. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. *Anticancer Drugs.* 2011 Feb;22(2):185-90.
 - Sastre J, Aranda E, Grávalos C, Massutí B, Varella-García M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E, Hidalgo M. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). *Crit Rev Oncol Hematol.* 2011 Jan;77(1):78-84. Epub 2009 Dec 29
 - Garre P, Pérez-Segura P, Díaz-Rubio E, Caldés T, de la Hoya M. Reassessing the TARBP2 mutation rate in hereditary nonpolyposis colorectal cancer. *Nat Genet.* 2010 Oct;42(10):817-8; author reply 818. No abstract available.
 - García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. *Clin Transl Oncol.* 2010 Aug;12(8):533-42.
 - Puente J, López-Tarruella S, Ruiz A, Lluch A, Pastor M, Alba E, de la Haba J, Ramos M, Cirera L, Antón A, Llombart A, Plazaola A, Fernández-Aramburo A, Sastre J, Díaz-Rubio E, Martín M. Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. *Breast Cancer Res Treat.* 2010 Jul;122(2):591-600. Epub 2010 Jan 10.
 - Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Díaz-Rubio E, Ducreux M, Geva R, Glimelius B, Glynne Jones R, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll HJ, Sobrero A, Tabernero J. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. *Ann Oncol.* 2010 Jun;21 Suppl 6:vi1-10.
 - Ortega P, Moran A, Fernandez-Marcelo T, De Juan C, Frias C, Lopez-Asenjo JA, Sanchez-Pernaute A, Torres A, Diaz-Rubio E, Iniesta P, Benito M. MMP-7 and SGCE as distinctive molecular factors in sporadic colorectal cancers from the mutator phenotype pathway. *Int J Oncol.* 2010 May;36(5):1209-15.

- Morán A, Ortega P, de Juan C, Fernández-Marcelo T, Frías C, Sánchez-Pernaute A, Torres AJ, Díaz-Rubio E, Iniesta P, Benito M. Differential colorectal carcinogenesis: Molecular basis and clinical relevance. *World J Gastrointest Oncol.* 2010 Mar 15;2(3):151-8.
- Pérez-Segura P, Bodas A, Sereno M, Martínez-Amores B, Olivera H, Díaz S, López-Asenjo JA, Puente J, Maluenda C, Díaz-Rubio E. Celecoxib in a 12-year-old boy with familial adenomatous polyposis. *Int J Clin Pharmacol Ther.* 2010 Mar;48(3):230-2.
- Puente J, Manzano A, Martín M, López-Tarruella S, Díaz-Rubio E. Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. *Anticancer Drugs.* 2010 Jan;21 Suppl 1:S19-22.
- Resel Folkersma L, Olivier Gómez C, San José Manso L, Veganzones de Castro S, Galante Romo I, Vidaurreta Lázaro M, de la Orden GV, Arroyo Fernández M, Díaz Rubio E, Silmi Moyano A, Maestro de Las Casas MA. Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation. *Arch Esp Urol.* 2010 Jan-Feb;63(1):23-31.
- Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardenosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.* 2010 Jan;119(1):221-32. Epub 2009 Apr 16.
- Dosil V, Tosar A, Cañadas C, Pérez-Segura P, Díaz-Rubio E, Caldés T, de la Hoya M. Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a case study. *Clin Chem.* 2010 Jan;56(1):53-61.
- Custodio A, Puente J, Sastre J, Díaz-Rubio E. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. *Cancer Treat Rev.* 2009 Dec;35(8):676-84. Epub 2009 Sep 15. Review.
- Maestro LM, Sastre J, Rafael SB, Veganzones SB, Vidaurreta M, Martín M, Olivier C, DE La Orden VB, García-Saenz JA, Alfonso R, Arroyo M, Diaz-Rubio E. Circulating tumor cells in solid tumor in metastatic and localized stages. *Anticancer Res.* 2009 Nov;29(11):4839-43.
- Frías C, Morán A, de Juan C, Ortega P, Fernández-Marcelo T, Sánchez-Pernaute A, Torres AJ, Díaz-Rubio E, Benito M, Iniesta P. Telomere function in colorectal cancer. *World J Gastrointest Oncol.* 2009 Oct 15;1(1):3-11.
- Martín M, García-Sáenz JA, Maestro De las Casas ML, Vidaurreta M, Puente J, Veganzones S, Rodríguez-Lajusticia L, De la Orden V, Oliva B, De la Torre JC, López-Tarruella S, Casado A, Sastre J, Díaz-Rubio E. Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. *Anticancer Res.* 2009 Oct;29(10):4185-7.
- García-Sáenz JA, Martín M, Maestro ML, Vidaurreta M, Veganzones S, Rafael S, Casado A, Bobokova J, Sastre J, De la Orden V, Arroyo M, Díaz-Rubio E. Circulating tumour cells in locally advanced breast cancer. *Clin Transl Oncol.* 2009 Aug;11(8):544-7.
- Custodio AB, González-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, Manzano A, Díaz-Rubio E. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. *J Thorac Oncol.* 2009 Jul;4(7):891-910. Review.
- Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. *Ann Oncol.* 2009 Jun;20 Suppl 7:vii1-vii6.
- Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Díaz-Rubio E. Consensus on the treatment of pancreatic cancer in Spain. *Clin Transl Oncol.* 2009 May;11(5):290-301. Review.
- Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B, Gómez-España A, González-Flores E, Rivera F, Losa F, García T, Sanchez-Rovira P, Maestu I, Díaz-Rubio E. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. *Crit Rev Oncol Hematol.* 2009 May;70(2):134-44. Epub 2008 Dec 25.

- Aranda E, Valladares M, Martínez-Villacampa M, Benavides M, Gomez A, Massutti B, Marcuello E, Constenla M, Cámara JC, Carrato A, Dueñas R, Reboredo MI, Navarro M, Díaz-Rubio E. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. *Ann Oncol.* 2009 Feb;20(2):251-7. Epub 2008 Aug 20.
- Arkenau HT, Arnold D, Cassidy J, Díaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. *J Clin Oncol.* 2008 Dec 20;26(36):5910-7. Epub 2008 Nov 17. Erratum in: *J Clin Oncol.* 2009 Dec 1;27(34):5859.
- Sastre J, Puente J, García-Saenz JA, Díaz-Rubio E. Irinotecan in the treatment of elderly patients with advanced colorectal cancer. *Crit Rev Oncol Hematol.* 2008 Dec;68(3):250-5. Epub 2008 Aug 23. Review
- Pérez Segura P, Jiménez P, Olivera H, Andrés Conejero R, Caldés T, de la Hoya M, Román JM, Moreno A, Puente J, Díaz-Rubio E. Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results. *Clin Transl Oncol.* 2008 Oct;10(10):660-4.
- Bodas A, Pérez-Segura P, Maluenda C, Caldés T, Olivera E, Díaz-Rubio E. Lynch syndrome in a 15-year-old boy. *Eur J Pediatr.* 2008 Oct;167(10):1213-5. Epub 2008 Jan 4.
- García-Sáenz JA, Martín M, Calles A, Bueno C, Rodríguez L, Bobokova J, Custodio A, Casado A, Díaz-Rubio E. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. *J Chemother.* 2008 Oct;20(5):632-9.
- Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Díaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Taberero J, Tempero M, Van de Velde C, Zalcberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. *Ann Oncol.* 2008 Jun;19 Suppl 6:vi1-8.
- Martínez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-Cardús A, Ginés A, Guino E; Spanish Group for the Treatment of Digestive Tumours. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. *Eur J Cancer.* 2008 Jun;44(9):1229-37. Epub 2008 Apr 28.
- Sastre J, Maestro ML, Puente J, Vezanzones S, Alfonso R, Rafael S, García-Saenz JA, Vidaurreta M, Martín M, Arroyo M, Sanz-Casla MT, Díaz-Rubio E. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. *Ann Oncol.* 2008 May;19(5):935-8. Epub 2008 Jan 22.
- Bueno Muiño C, García-Sáenz JA, Santos Martín E, Sastre J, Mayol J, Díaz-Rubio E. Successful rectal cancer local recurrence radiofrequency ablation. *Clin Transl Oncol.* 2008 May;10(5):300-2.
- Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol.* 2008 Apr 20;26(12):2013-9. Erratum in: *J Clin Oncol.* 2008 Jun;26(18):3110. *J Clin Oncol.* 2009 Feb 1;27(4):653.
- Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/foinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol.* 2008 Apr 20;26(12):2006-12.
- Abad A, Massuti B, Antón A, Vega ME, Yuste AL, Marcuello E, Manzano JL, Alonso V, Carrato A, Martínez-Villacampa M, Taberero J, Aranda E, Rivera F, Díaz-Rubio E; Spanish Cooperative Group for Digestive Tumor Therapy. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. *Acta Oncol.* 2008;47(2):286-92.
- Taberero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont

- A. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol*. 2007 Nov 20;25(33):5225-32.
- Abad A, Figueras J, Valls C, Carrato A, Pardo F, Díaz-Rubio E, Aranda E. Guidelines for the detection and treatment of liver metastases of colorectal cancer. *Clin Transl Oncol*. 2007 Nov;9(11):723-30. Review.
 - Sánchez-de-Abajo A, de la Hoya M, van Puijenbroek M, Tosar A, López-Asenjo JA, Díaz-Rubio E, Morreau H, Caldes T. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. *Clin Cancer Res*. 2007 Oct 1;13(19):5729-35.
 - Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. *J Clin Oncol*. 2007 Sep 20;25(27):4224-30. Epub 2007 Jun 4.
 - Vidaurreta M, Sastre J, Sanz-Casla MT, Maestro ML, Rafael S, Díaz-Rubio E. [Detection and quantification of circulating tumor cells in peripheral blood in patients with colon cancer]. *Med Clin (Barc)*. 2007 Sep 15;129(9):333-4. Spanish.
 - García Sáenz JA, López Tarruella S, García Paredes B, Rodríguez Lajusticia L, Villalobos L, Díaz Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. *Med Oral Patol Oral Cir Bucal*. 2007 Sep 1;12(5):E351-6.
 - Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmol HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. *Ann Oncol*. 2007 Jun;18 Suppl 7:vii1-vii10.
 - Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. *J Clin Oncol*. 2007 Jun 1;25(16):2171-7.
 - Cañadas C, Sánchez-de-Abajo A, Fernández JM, Martín M, Diaz-Rubio E, Caldés T, de la Hoya M. Molecular haplotyping of tandem single nucleotide polymorphisms by allele-specific PCR. *Anal Biochem*. 2007 May 15;364(2):153-8. Epub 2007 Mar 3.
 - Gutiérrez-Enríquez S, de la Hoya M, Martínez-Bouzas C, Sanchez de Abajo A, Ramón y Cajal T, Llorca G, Blanco I, Beristain E, Díaz-Rubio E, Alonso C, Tejada MI, Caldés T, Diez O. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. *Breast Cancer Res Treat*. 2007 May;103(1):103-7. Epub 2006 Oct 25.
 - Paz-Ares L, Rivera-Herreros F, Díaz-Rubio E, García M, Casado E, Cubedo R, Gravalos C, Alfaro V, Gómez J, Izquierdo MA, Tabernero J. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer. *Clin Colorectal Cancer*. 2007 May;6(7):522-8.
 - Bueno Muiño C, Puente Vázquez J, Sastre Valera J, García-Sáenz JA, Martín M, García Miralles N, Sánchez-Pernaute A, Díaz-Rubio E. Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. *Clin Transl Oncol*. 2007 May;9(5):335-8. Review.
 - García-Saénz JA, Martín M, Díaz-Rubio E. Elementary, my dear Watson. *J Clin Oncol*. 2007 May 1;25(13):1815-6. No abstract available.
 - Pérez-Segura P, Siso I, Luque R, Olivera H, Díaz S, Mayol J, Bueno C, Puente J, Díaz-Rubio E. Iatrogenic intestinal obstruction: a rare complication of capsule endoscopy in a patient with familial adenomatous polyposis. *Endoscopy*. 2007 Feb;39 Suppl 1:E298-9. Epub 2007 Oct 24. No abstract available.



- Hanauske AR, Cassidy J, Sastre J, Bolling C, Jones RJ, Rakhit A, Fettner S, Brennscheidt U, Feyereislova A, Díaz-Rubio E. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. *Clin Cancer Res.* 2007 Jan 15;13(2 Pt 1):523-31.
- Vázquez JP, Cobo SL, Antón FM, Asado AC, Vidart JA, Coronado P, Díaz-Rubio E. Brain metastasis and carcinomatous meningitis from vulvar squamous cell carcinoma: case report. *Eur J Gynaecol Oncol.* 2007;28(2):152-4.